Cardiovascular disease is the leading cause of death and disability among adults worldwide, while metabolic diseases is the growing factor which contributes to the occurrence and development of cardiovascular diseases. Despite recent progresses in the research and development, we see urgent and large unmet needs in the prevention and treatment of these diseases globally.

CORXEL was founded as a global biotech dedicated to the development of cardiometabolic disease therapies, with the goal of bringing breakthrough treatment solutions to ease the disease burden of patients and their families worldwide. 

CORXEL has established global development capability for our lead assets, JX09 and JX10, two investigational new drugs with global breakthrough potential for the treatment of hypertension and acute ischemic stroke, respectively.

We will continue to expand the portfolio in the therapeutic areas under cardiometabolic disease. The long-term goal for the company is to lead the treatment of these diseases with innovative therapies for patients globally.

Our global team based in the United States and China has the advantage to access KOLs, Clinical study sites and patients in both regions to execute clinical studies with tremendous speed. CORXEL is well equipped with seasoned Medical, Clinical, CMC, Registrational and Business Development professionals in both locations, covering the two largest patient populations in the world.

We are fully committed to conducting each clinical study with quality and efficiency, to provide global cardiometabolic patients in need with life-changing, and potentially life-saving therapies.